Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain

被引:77
作者
Burkey, TH
Quock, RM
Consroe, P
Ehlert, FJ
Hosohata, Y
Roeske, WR
Yamamura, HI
机构
[1] UNIV ARIZONA,HLTH SCI CTR,COLL MED,DEPT PHARMACOL,TUCSON,AZ 85724
[2] UNIV ARIZONA,HLTH SCI CTR,COLL MED,DEPT PHARMACOL & TOXICOL,TUCSON,AZ 85724
[3] UNIV ARIZONA,HLTH SCI CTR,COLL MED,DEPT BIOCHEM,TUCSON,AZ 85724
[4] UNIV ARIZONA,HLTH SCI CTR,COLL MED,DEPT PSYCHIAT,TUCSON,AZ 85724
[5] UNIV ARIZONA,HLTH SCI CTR,COLL MED,PROGRAM NEUROSCI,TUCSON,AZ 85724
[6] UNIV ILLINOIS,COLL MED,DEPT BIOMED SCI,ROCKFORD,IL 61107
[7] UNIV CALIF IRVINE,DEPT PHARMACOL,IRVINE,CA 92717
关键词
cannabinoid; cannabinoid receptor; drug efficacy; brain; mouse; (partial agonist); tetrahydrocannabinol;
D O I
10.1016/S0014-2999(97)01255-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We measured (-)-5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol (CP 55,940)-, (-)11-OH-Delta (8)-tetrahydrocannabinol-dimethylheptyl (HU-210)-, anandamide- and Delta(9)-tetrahydrocannabinol-stimulated G protein activation in mouse brain using the [S-35]GTPyS functional assay. The K-i values for these drugs were determined by agonist competition binding with the cannabinoid CB, receptor antagonist [H-3]N-(piperidin-1-yl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamidehydrochloride ([H-3]SR141716A). This information was used to calculate the efficacy for drug stimulation of G protein activity. The rank order of efficacy was CP 55,940 > HU-210 > anandamide > Delta(9)-tetrahydrocannabinol with the latter two drugs being partial agonists. Since efficacy values relate receptor occupancy to functional responses, we believe efficacy values are a better measure of drug-mediated functional responses compared with measurements of drug potency. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:295 / 298
页数:4
相关论文
共 50 条
  • [41] Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor
    Khajehali, Elham
    Malone, Daniel T.
    Glass, Michelle
    Sexton, Patrick M.
    Christopoulos, Arthur
    Leach, Katie
    MOLECULAR PHARMACOLOGY, 2015, 88 (02) : 368 - 379
  • [42] Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents
    Wade, Mark R.
    Degroot, Aldemar
    Nomikos, George G.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 551 (1-3) : 162 - 167
  • [43] The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus
    Takahashi, K. A.
    Castillo, P. E.
    NEUROSCIENCE, 2006, 139 (03) : 795 - 802
  • [44] An overview of cannabinoid receptor 1 (CB1) and therapeutic approaches-I
    Cinar, Resat
    Cinar, Ozge Gunduz
    CLINICAL AND EXPERIMENTAL HEALTH SCIENCES, 2011, 1 (03): : 149 - 154
  • [45] Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization
    Jin, WZ
    Brown, S
    Roche, JP
    Hsieh, C
    Celver, JP
    Kovoor, A
    Chavkin, C
    Mackie, K
    JOURNAL OF NEUROSCIENCE, 1999, 19 (10) : 3773 - 3780
  • [46] Discovery of indole alkaloids with cannabinoid CB1 receptor antagonistic activity
    Kitajima, Mariko
    Iwai, Masumi
    Kikura-Hanajiri, Ruri
    Goda, Yukihiro
    Iida, Mitsuru
    Yabushita, Hisatoshi
    Takayama, Hiromitsu
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (07) : 1962 - 1964
  • [47] Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist
    Amaya, Fumimasa
    Shimosato, Goshun
    Kawasaki, Yasuhiko
    Hashimoto, Satoru
    Tanaka, Yoshifumi
    Ji, Ru-Rong
    Tanaka, Masaki
    PAIN, 2006, 124 (1-2) : 175 - 183
  • [48] Homology model of the CB1 cannabinoid receptor:: Sites critical for nonclassical cannabinoid agonist interaction
    Shim, JY
    Welsh, WJ
    Howlett, AC
    BIOPOLYMERS, 2003, 71 (02) : 169 - 189
  • [49] Synthesis and pharmacological characterization of functionalized 6-piperazin-1-yl-purines as cannabinoid receptor 1 (CB1) inverse agonists
    Amato, George S.
    Manke, Amruta
    Vasukutta, Vineetha
    Wiethe, Robert W.
    Snyder, Rodney W.
    Runyon, Scott P.
    Maitra, Rangan
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (15) : 4518 - 4531
  • [50] Chronic insulinopenia/hyperglycemia decreases cannabinoid CB1 receptor density and impairs glucose uptake in the mouse forebrain
    Moura, Liane I. F.
    Lemos, Cristina
    Ledent, Catherine
    Carvalho, Eugenia
    Kofalvi, Attila
    BRAIN RESEARCH BULLETIN, 2019, 147 : 101 - 109